Author

Fabrizio De Ponti

Professor of Pharmacology, University of Bologna - Cited by 12,450 - Pharmacology

Biography

Dr. Fabrizio De Ponti is working as a Professor of Pharmacology in the Department of Medical and Surgical Sciences, School of Medicine at University of Bologna, Bologna, Italy. He has received degree of Medical Doctor at University of Pavia in the year of 1983. After that in the year of 1990 he earned degree of Ph D in Pharmacology and Toxicology at University of Turin.  He has authored more than 150 publications in many international journals. He is an active member of Italian Pharmacological Society; British Pharmacological Society; American Gastroenterological Association; American Neurogastroenterology and Motility Society.
Title
Cited by
Year
Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance
E Raschi, M Gatti, F Gelsomino, A Ardizzoni, E Poluzzi, F De PontiTargeted Oncology 15, 449-466, 2020202
79
2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
E Raschi, M Fusaroli, A Ardizzoni, E Poluzzi, F De PontiBreast Cancer Research and Treatment 186, 219-227, 2021202
43
2021
Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID‐19
M Gatti, M Fusaroli, P Caraceni, E Poluzzi, F De Ponti, E RaschiBritish journal of clinical pharmacology 87 (3), 1533-1540, 2021202
42
2021
Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities
M Gatti, F De PontiPharmaceutics 13 (3), 302, 2021202
27
2021
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
M Gatti, E Raschi, F De PontiEuropean journal of clinical pharmacology 77, 233-239, 2021202
26
2021
Serotonin modulation of gastrointestinal motility
M Tonini, F De PontiSerotonin and gastrointestinal function, 53-84, 2020202
25
2020
Liver injury with ulipristal acetate: exploring the underlying pharmacological basis
M Gatti, E Poluzzi, F De Ponti, E RaschiDrug Safety 43, 1277-1285, 2020202
25
2020
Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
E Raschi, IC Antonazzo, E Poluzzi, F De PontiAnnals of the Rheumatic Diseases 80 (7), e120-e120, 2021202
25
2021
Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems
M Gatti, I Ippoliti, E Poluzzi, IC Antonazzo, PA Moro, U Moretti, ...Clinical Nutrition 40 (3), 1176-1185, 2021202
23
2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
M Gatti, IC Antonazzo, I Diemberger, F De Ponti, E RaschiEuropean journal of preventive cardiology 28 (9), 983-989, 2021202
23
2021
Risk of hospitalization from drug-drug interactions in the elderly: real-world evidence in a large administrative database
F Swart, G Bianchi, J Lenzi, M Iommi, L Maestri, E Raschi, M Zoli, ...Aging (Albany NY) 12 (19), 19711, 2020202
17
2020
Thromboembolic events with cyclin-dependent kinase 4/6 inhibitors in the FDA adverse event reporting system
E Raschi, M Fusaroli, A Ardizzoni, E Poluzzi, F De PontiCancers 13 (8), 1758, 2021202
16
2021
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
E Raschi, P Caraceni, E Poluzzi, F De PontiExpert Opinion on Drug Safety 19 (10), 1367-1369, 2020202
15
2020
Biomarkers of kidney injury in very-low-birth-weight preterm infants: influence of maternal and neonatal factors
I Capelli, F Vitali, F Zappulo, S Martini, C Donadei, M Cappuccilli, ...in vivo 34 (3), 33-39, 2020202
13
2020
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing
M Gatti, M Giannella, E Raschi, P Viale, F De PontiJournal of Antimicrobial Chemotherapy 76 (1), 199-205, 2021202
12
2021
Clinically significant drug interactions between psychotropic agents and repurposed COVID-19 therapies
M Gatti, F De Ponti, F PeaCNS drugs 35 (4), 345-384, 2021202
11
2021
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: A large-scale pharmacovigilance analysis
M Gatti, E Raschi, F De PontiEuropean Journal of Clinical Microbiology & Infectious Diseases 40 (6), 1169 …, 2021202
8
2021
Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system
E Raschi, M Fusaroli, M La Placa, A Ardizzoni, C Zamagni, E Poluzzi, ...American Journal of Clinical Dermatology, 1-9, 2021202
7
2021
The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice
E Raschi, M La Placa, E Poluzzi, F De PontiBritish Journal of Dermatology 184 (3), 581-583, 2021202
7
2021
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
M Gatti, M Fusaroli, E Raschi, U Moretti, E Poluzzi, F De PontiExpert Opinion on Drug Safety 20 (11), 1421-1431, 2021202
7
2021

Referred From: https://scholar.google.com/citations?user=-uKkN68AAAAJ&hl=it

Cited by
Citations 12450
h-index 62
i10-index 200
Recommended Journals
Open Access Journals